Summary by Moomoo AI
Wing Cheong Biopharmaceuticals (Yantai) Co., Ltd. (“Wing Cheong Biologics”) plans to issue A shares to selected audiences in 2024 to increase the company's total share capital and net assets, and further optimize its research pipeline, enhance core competitiveness and strengthen its product market position. According to the company's 2023 report, the company's 2023 net profit is negative, and the net profit in 2024 is forecast to increase, level or decrease. Upon completion of the issuance, the Company will take measures to prevent future returns from being diluted, with commitments made by its controlling shareholders, controllers and senior management. In addition, the company emphasizes that the fundraising investment projects will contribute to the company's continued healthy development and comply with the country's relevant industrial policies and the company's future development strategy. The announcement date is 30 March 2024.